Tag: Takeda Pharmaceutical

Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China

Raghuram Kadari- January 24, 2023

Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More

Takeda gets QDENGA EC approval as dengue vaccine

Raghuram Kadari- December 12, 2022

Takeda has received the European Commission’s (EC) marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine ) (TAK-003). The QDENGA vaccine is indicated ... Read More

Strides Pharma Science gets FDA approval for Colchicine Tablets generic

- March 13, 2022

Strides Pharma Science Limited said that its Singapore-based stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited has secured approval for Colchicine Tablets USP, 0.6 ... Read More

Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

pharmanewsdaily- September 11, 2020

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More

Takeda to sell select non-core assets to Cheplapharm for $562m

pharmanewsdaily- September 9, 2020

Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm ... Read More

Takeda to divest consumer healthcare business to Blackstone for $2.3bn

pharmanewsdaily- August 24, 2020

Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The ... Read More

Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

pharmanewsdaily- August 8, 2020

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More

Takeda gets extended EC approval for ADCETRIS in sALCL

pharmanewsdaily- May 17, 2020

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More

Takeda Pharmaceutical to sell OTC and non-core products to Orifarm

pharmanewsdaily- April 25, 2020

Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a ... Read More

Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics

pharmanewsdaily- February 28, 2020

Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth ... Read More